Facts
- HQ
- Seattle
- Sectors
- Biotechnology
Is this your organization? Claim it
GeekWire's Top Stories for July 14, 2024: Microsoft D&I Updates, NYC Delivery Wage Rise, Seattle Startup Momento Raises $15M
GeekWire's most popular stories for the week of July 14, 2024, cover Microsoft's diversity and inclusion efforts, NYC's minimum wage impact on delivery drivers, Seattle startup Momento's $15M funding, and new visa centers and VR venues opening in the Seattle area.
Seagen Founder Clay Siegall Named CEO of Purdue Spinout Morphimmune After Resigning in 2023
Clay Siegall, founder and former CEO of Seagen, has returned to biotech as CEO and president of Morphimmune, a Purdue University spinout relocating to Seattle. This move follows his resignation from Seagen in May 2023 and precedes Pfizer's planned $43 billion acquisition of Seagen.
Umoja Biopharma raises $210M Series B to advance in‑vivo T‑cell immunotherapies after $53M Series A seven months earlier
Umoja Biopharma, a Seattle-based immunotherapy startup, raised $210 million in a Series B just seven months after a $53 million Series A to advance in‑vivo T‑cell cancer therapies and tumor‑tagging technology into clinical trials for solid and hematological tumors.
See all 4 stories, episodes and videos about Morphimmune.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events